BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioLineRx Ltd. In-Licenses Novel Technology From Galmed International, Ltd. For The Treatment Of Fatty Liver Disease; Innovative Small Molecule Has Potential For A One Billion Dollar Per Year Market


10/19/2005 5:13:00 PM

JERUSALEM--(BUSINESS WIRE)--March 14, 2005--BioLineRx Ltd., Israel's leading specialized drug development company, today announced that it has signed a license agreement for the development and commercialization of BL-1060, a small molecule for the treatment of fatty liver disease. The worldwide exclusive license agreement was signed with Galmed International Ltd. BioLineRx plans to develop the project through BioLine Innovations Jerusalem and to submit the project for funding by the Israeli Office of the Chief Scientist under the National Biotech Grant that BioLineRx received in November of this year. The primary indication for BL-1060 is fatty liver disease (including nonalcoholic steatohepatitis or NASH), which is associated with the near epidemic of obesity and diabetes. Fatty liver is a condition that has only recently been recognized as a discrete and extremely common liver disease by the medical community. Researchers believe that the insulin resistance that develops secondary to obesity is the cause of both the dramatic increase in the number of type 2 diabetic patients, and the increasing prevalence of fatty liver disease. The number of patients experiencing obesity, insulin resistance, and related pathologies are expected to eclipse 300 million worldwide by 2025. Fatty liver disease now ranks as the third leading cause of chronic liver failure, behind alcoholic liver disease and viral hepatitis.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES